Kevin Ross Holme

Title: Kevin Ross Holme: Innovator in Pharmaceutical Development

Introduction

Kevin Ross Holme is a notable inventor based in San Diego, California. He has made significant contributions to the field of pharmaceuticals, particularly in the development of inhibitors related to lysyl oxidase-like 2 (LOXL2). With a total of six patents to his name, Holme's work has the potential to impact the treatment of various conditions associated with LOXL2 activity.

Latest Patents

Holme's latest patents focus on crystalline forms of a lysyl oxidase-like 2 inhibitor and methods of making it. The patent describes crystalline forms of pharmaceutically acceptable salts of the LOXL2 inhibitor, specifically the compound (3-(4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yloxy)phenyl)((3R,4R)-3-fluoro-4-hydroxypyrrolidin-1-yl)methanone. Additionally, the patent outlines methods for synthesizing the LOXL2 inhibitor, as well as pharmaceutical compositions and medicaments that incorporate this inhibitor. These innovations are aimed at treating conditions, diseases, or disorders linked to LOXL2 activity.

Career Highlights

Throughout his career, Kevin Ross Holme has worked with prominent companies in the pharmaceutical industry. Notable among these are Lion Bioscience AG and Pharmakea, Inc. His experience in these organizations has contributed to his expertise in drug development and innovation.

Collaborations

Holme has collaborated with several professionals in his field, including Timothy Gahman and Karen J. Watson-Straughan. These collaborations have likely enhanced his research and development efforts, leading to successful innovations in pharmaceutical applications.

Conclusion

Kevin Ross Holme is a distinguished inventor whose work in the pharmaceutical sector has led to significant advancements in the treatment of diseases associated with LOXL2 activity. His contributions through patents and collaborations continue to shape the future of medical treatments.